Bexion Pharmaceuticals, Inc. to Present at the 2022 European Association of Neuro-Oncology (EANO 2022)

FOR IMMEDIATE RELEASE [Covington, KY— 14 September 2022]

Bexion Pharmaceuticals, Inc., a mid-stage clinical biopharmaceutical company developing a new generation of biologic immunotherapy to treat solid tumor cancers and Chemotherapy Induced Peripheral Neuropathy (CIPN), announced today that an abstract submitted for an in-person session at the EANO annual meeting to be held in Vienna, Austria from September 15-18, 2022 has been chosen for poster presentation.

EANO is Europe’s multidisciplinary Neuro-Oncology organization representing all medical and scientific disciplines involved in the prevention, diagnosis and treatment of tumors of the central nervous system (CNS). EANO is dedicated to promoting advances in Neuro-Oncology through innovative research and concerted education and training. It enhances collaboration between all relevant disciplines – Neuro-Oncology, Neurosurgery, Neuropathology, Neuroradiology, and Radiation Oncology as well as Nursing – and aims at bridging science, knowledge, and practice gaps in the management of CNS malignancies.

Title of the Abstract-Poster Presentation:

BXQ-350: Modulating ceramide and Sphingosine-1 Phosphate for anti-tumor activity and potential mitigation of chemotherapy-induced peripheral neuropathy

Poster Presentation Session:

Friday September 16, 18:00-19:30 hrs (CEST)
Saturday, September 17, 17:00-18:30 hrs (CEST)

Gilles Tapolsky, Ph.D., M.B.A., Vice President, Pharmacology at Bexion will be discussing the key findings from these poster presentations.

About Bexion Pharmaceuticals

Bexion Pharmaceuticals, a clinical-stage biopharmaceutical company, is developing a new generation of biologic immunotherapy to treat solid tumor cancers and Chemotherapy Induced Peripheral Neuropathy (CIPN) with potential portfolio expansion opportunities in other cancers and broader neuropathic pain indications. Bexion’s lead drug candidate is BXQ-350, a first-in-class biologic containing the multifunctional, lysosomal activator protein, Saposin C and a phosphatidylserine.
BXQ-350, an “S1P Activator”, has demonstrated pre-clinical antitumor effects in vitro and in vivo, particularly in colorectal, brain and other solid tumors. Bexion has completed two single agent Phase 1 programs in adults and in a pediatric population. The Phase 1 programs demonstrated a strong safety profile with evidence of single agent activity across a range of tumors including Glioblastoma Multiforme (GBM), colorectal cancer and appendiceal cancer. Additionally, other clinical and non-clinical data suggest BXQ-350 has activity in chemotherapy induced peripheral neuropathy.

Media Contact: Margaret van Gilse ●859.757.1652 ● [email protected]